On Monday, Morgan Stanley (NYSE:MS) adjusted its outlook on Alnylam Pharmaceuticals, a company listed on NASDAQ:ALNY, by increasing the price target to $250 from the previous $164, while keeping the stock's rating at Equalweight. The revision comes after the firm reviewed the top-line results of the HELIOS-B study, which they found to exceed expectations.
The HELIOS-B study outcomes are anticipated to pave the way for a supplemental New Drug Application (sNDA) filing in late 2024. Morgan Stanley's analyst highlighted the significance of these results in the context of Alnylam's future prospects. The next major event for the company is the presentation of detailed data at the European Society of Cardiology (ESC) in the fourth quarter of 2024, which is expected to offer more insights into the drug's competitive stance in the market.
The firm's decision to maintain an Equalweight rating indicates that they view the stock as adequately valued at the current levels, but the new price target suggests a potential upside based on the recent study findings. The HELIOS-B study results have provided a positive signal for Alnylam Pharmaceuticals as it continues to develop its drug pipeline and seeks to strengthen its position in the pharmaceutical industry.
The markets are likely to watch closely as Alnylam Pharmaceuticals prepares for the detailed presentation at the ESC later this year. This event is set to give investors and stakeholders a clearer picture of the drug's market potential and the company's strategic direction moving forward.
In other recent news, Alnylam Pharmaceuticals has reported positive outcomes from its HELIOS-B Phase 3 trial for vutrisiran, a drug designed for ATTR amyloidosis with cardiomyopathy. This trial resulted in a significant reduction in mortality and recurrent cardiovascular events in patients. Following this, Alnylam plans to file for global regulatory approval for vutrisiran.
Meanwhile, BridgeBio Pharma (NASDAQ:BBIO)'s ATTRibute-CM trial has set a high bar with a p-value of 0.0008, indicating a strong performance in comparison to Alnylam's study. TD Cowen maintains a Buy rating on BridgeBio shares, highlighting the significance of these trial outcomes.
On the financial front, Alnylam's Q1 2024 revenues reached $365 million, marking a 32% increase from the same period the previous year, largely driven by its Transthyretin (TTR) franchise. The company is targeting net product revenues between $1.4 billion and $1.5 billion for 2024.
Analyst firms Stifel, RBC Capital, and BMO Capital have all maintained positive ratings for Alnylam following the promising study results.
InvestingPro Insights
As Alnylam Pharmaceuticals (NASDAQ:ALNY) garners attention following Morgan Stanley's updated price target, InvestingPro data provides additional context for investors evaluating the company's financials and market performance. With a substantial market capitalization of $28.46 billion, Alnylam stands out as a significant player in the biopharmaceutical space. Notably, the company has demonstrated impressive revenue growth, with a 75.2% increase over the last twelve months as of Q1 2024. This growth is further underscored by a quarterly revenue increase of 54.82% in Q1 2024, signaling robust financial performance.
Despite not being profitable in the last twelve months, with a P/E ratio of -85.81, Alnylam's gross profit margin remains high at 83.95%. Investors may find reassurance in the fact that the company's liquid assets exceed its short-term obligations, pointing to financial stability. Moreover, Alnylam's stock has been trading near its 52-week high, reflecting strong investor confidence which aligns with Morgan Stanley's optimistic price target.
InvestingPro Tips highlight that Alnylam operates with a moderate level of debt and has had a strong return over the last five years, although it does not pay dividends to shareholders. For investors seeking a deeper dive into Alnylam's financials and strategic positioning, InvestingPro offers additional tips to inform investment decisions. Using the coupon code PRONEWS24, investors can access these insights at a discounted rate on a yearly or biyearly Pro and Pro+ subscription. With seven additional InvestingPro Tips available, investors can gain a comprehensive understanding of Alnylam Pharmaceuticals' investment profile.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.